Almotriptan

Almotriptan

File:Almatriptan.svg
Clinical data
Pregnancy category	C(USA)
Routes of administration	Oral
ATC code	N02CC05 (WHO)
Legal status
Legal status	Prescription only
Pharmacokinetic data
Bioavailability	70%
Protein binding	35%
Elimination half-life	3-4 hours
Identifiers
IUPAC name N,N-dimethyl-2- [5-(pyrrolidin-1-ylsulfonylmethyl)- 1H-indol-3-yl]-ethanamine
CAS Number	154323-57-6
PubChem CID	123606
DrugBank	APRD00169
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C17H25N3O2S
Molar mass	335.465 g/mol

Almotriptan (Axert®, Almogran®) is a triptan drug discovered by Almirall Prodesfarma and licensed to Ortho-McNeil for the treatment of migraine headaches. It is available in strengths of 6.25 and 12.5 mg as a tablet.

In the United States and Canada almotriptan is available under the name Axert® only by prescription. AXERT® for oral administration contains almotriptan malate equivalent to 6.25 or 12.5 mg of almotriptan. Each compressed tablet contains the following inactive ingredients: mannitol, cellulose, povidone, sodium starch glycolate, sodium stearyl fumarate, titanium dioxide, hypromellose, polyethylene glycol, propylene glycol, iron oxide (6.25 mg only), FD&C Blue No. 2 (12.5 mg only), and carnauba wax. The brand Almogran is used in Belgium, Finland, France, Germany, Italy, Portugal, Spain and the United Kingdom. Each 12.5 mg. tablet contains the following inactiva ingredients: carnauba wax, hypromellose, indigo carmine (E132), macrogol 400, mannitol, microcrystalline cellulose, povidone, propylene glycol, sodium starch glycollate, sodium stearyl fumarate and titanium dioxide (E171).

External links

• R&D page by Almirall Prodesfarma
• Axert Official homepage by Ortho-McNeil

Template:Pharma-stub